AI Article Synopsis
- The study investigates the impact of Bruton tyrosine kinase (BTK) inhibitor ibrutinib on vaccine responses in chronic lymphocytic leukemia patients, comparing them with matched controls.
- It was found that patients on ibrutinib had varied immune responses: 40% responded to diphtheria and 30% to tetanus, while none responded to Pneumovax, but these differences were not statistically significant.
- The authors conclude that ibrutinib does not significantly hinder vaccine responses, emphasizing the need for larger studies to explore the long-term immunological effects, particularly in those previously treated with anti-CD20 monoclonal antibodies.
Article Abstract
Objective/background: In the era of novel agents, Bruton tyrosine kinase (BTK) inhibitors have changed the dynamics of treating chronic lymphocytic leukemia. However, small studies have shown conflicting results regarding the additive humoral dysfunction with their use.
Methods: We prospectively compared vaccine responses in patients on ibrutinib (n = 10) with matched controls (n = 16) and analyzed whether a protein-based (tetanus-diphtheria toxoid) or a carbohydrate (Pneumovax) moiety will result in an improved immunological response.
Results: An appropriate serological response in IgG titers for diphtheria was seen in 40% of patients on ibrutinib and 31% of patients in the control group. About 30% of patients on ibrutinib and 44% of patients in the control group had an adequate response to tetanus toxoid. None of the patients on ibrutinib mounted an adequate response to Pneumovax, while 31% of patients in the control arm responded appropriately. These differences in the results were considered insignificant as all p values were greater than the cut-off of 0.05.
Conclusion: Our study did not show significant detrimental vaccine responses with ibrutinib and calls for larger multicenter studies to elucidate long-term effects, especially in patients with prior exposure to anti-CD20 monoclonal antibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hemonc.2021.07.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!